This Stock Could Be the Tesla of Healthcare – Madison.com
|
This Stock Could Be the Tesla of Healthcare
Madison.com The company has licensed exclusive rights to patents for the use of CRISPR-Cas9 in editing eukaryotic cells (i.e., any cells with a nucleus, including all human and animal cells). Editas also licensed patents to another type of gene editing, CRISPR … Editas Medicine, Inc. (NASDAQ:EDIT) Closed 7.2% Above Its 50 Day Moving Average |
